The Pathogenesis of Neural Injury in Animal Models of the Antiphospholipid Syndrome

被引:38
|
作者
Katzav, Aviva [1 ,2 ]
Shoenfeld, Yehuda [3 ,4 ]
Chapman, Joab [1 ,2 ]
机构
[1] Chaim Sheba Med Ctr, Dept Neurol, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Joseph Sagol Neurosci Ctr, IL-52621 Tel Hashomer, Israel
[3] Chaim Sheba Med Ctr, Dept Med B, Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
[4] Chaim Sheba Med Ctr, Dept Res, Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
基金
以色列科学基金会;
关键词
Antiphospholipid syndrome; Antiphospholipid antibodies; Neurology; Behavior; Dementia; Epilepsy; Chorea; Animal models; ANTI-BETA(2)-GLYCOPROTEIN I ANTIBODIES; ACTIVATED PROTEIN-KINASE; COGNITIVE DEFICITS; HUGHES-SYNDROME; THROMBIN INHIBITION; ENDOTHELIAL-CELLS; PREGNANT RABBITS; TISSUE FACTOR; MOUSE MODEL; BRAIN;
D O I
10.1007/s12016-009-8154-x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Circulating antiphospholipid antibodies (aPL) are associated with central nervous system dysfunction in antiphospholipid syndrome (APS) patients and in a mouse model of APS. We propose a logical pathway of how experimental APS (eAPS) causes brain dysfunction: binding of the antibodies to the brain endothelium evoking microthrombosis, endothelial dysfunction, and IgG leakage through the blood-brain barrier (BBB), then secondary inflammatory cell spread around blood vessels and production of cytokines by these inflammatory cells leading to further disruption of the BBB. The diffuse brain endothelial dysfunction would result in extravasation of serum proteins including APS IgG and activated thrombin, which may induce the behavioral changes observed in the APS mice. We have collected data from the mouse eAPS model which supports this hypothesis. Elucidating the mechanism of the pathogenicity of aPL in vitro and in vivo will serve as a much needed basis for developing new therapeutic modalities in this important disorder.
引用
收藏
页码:196 / 200
页数:5
相关论文
共 50 条
  • [1] The Pathogenesis of Neural Injury in Animal Models of the Antiphospholipid Syndrome
    Aviva Katzav
    Yehuda Shoenfeld
    Joab Chapman
    Clinical Reviews in Allergy & Immunology, 2010, 38 : 196 - 200
  • [2] Animal models of antiphospholipid syndrome
    Tincani, A
    Spatola, L
    Cinquini, M
    Meroni, P
    Balestrieri, G
    Shoenfeld, Y
    REVUE DU RHUMATISME, 1998, 65 (11): : 614 - 618
  • [3] Animal models of the antiphospholipid syndrome
    Radway-Bright, EL
    Inanc, M
    Isenberg, DA
    RHEUMATOLOGY, 1999, 38 (07) : 591 - 601
  • [4] Animal models for antiphospholipid syndrome in pregnancy
    Ziporen, L
    Blank, M
    Shoenfeld, Y
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1997, 23 (01) : 99 - &
  • [5] Antiphospholipid syndrome: insights from animal models
    Sherer, Y
    Shoenfeld, Y
    CURRENT OPINION IN HEMATOLOGY, 2000, 7 (05) : 321 - 324
  • [6] Progress in the field of animal models of antiphospholipid syndrome
    Gao, Xinnan
    Ma, Dan
    Mi, Liangyu
    Zhao, Jingwen
    An, Qi
    Guo, Zhiying
    Yang, Baoqi
    Zhang, Liyun
    Xu, Ke
    AUTOIMMUNITY, 2024, 57 (01)
  • [7] Antiphospholipid syndrome in pregnancy - animal models and clinical implications
    Shoenfeld, Y
    Sherer, Y
    Blank, M
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1998, : 33 - 36
  • [8] Pathogenesis of antiphospholipid syndrome
    Galli, M
    THROMBOSIS RESEARCH, 2005, 115 : 103 - 107
  • [9] The Pathogenesis of the Antiphospholipid Syndrome
    Giannakopoulos, Bill
    Krilis, Steven A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (11): : 1033 - 1044
  • [10] The Pathogenesis of the Antiphospholipid Syndrome
    Million, Matthieu
    Raoult, Didier
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (24): : 2335 - 2335